Table 1.
Patient Demographics and Baseline Disease Characteristics
| Copanlisib Plus R-B SRI (N = 10) |
Copanlisib Plus R-CHOP SRI (N = 11) |
Total (N = 21) | |
|---|---|---|---|
| Females | 8 (80.0) | 5 (45.5) | 13 (61.9) |
| Age (y), median (range) | 62 (41-82) | 64 (46-78) | 63 (41-82) |
| ECOG performance status | |||
| 0 | 5 (50.0) | 8 (72.7) | 13 (61.9) |
| 1 | 5 (50.0) | 3 (27.3) | 8 (38.1) |
| Histology of lymphoma | |||
| Follicular lymphoma | 7 (70.0) | 11 (100) | 18 (85.7) |
| Extranodal marginal zone lymphoma or MALT lymphoma | 1 (10.0) | 0 | 1 (4.8) |
| Lymphoplasmacytic lymphoma | 1 (10.0) | 0 | 1 (4.8) |
| Waldenström macroglobulinemia | 1 (10.0) | 0 | 1 (4.8) |
| Grade of follicular lymphomaa | |||
| 1 | 5 (50.0) | 0 | 5 (23.8) |
| 2 | 2 (20.0) | 7 (63.6) | 9 (42.9) |
| 3a | 0 | 4 (36.4) | 4 (19.0) |
| Stage at study entryb | |||
| I | 1 (10.0) | 2 (18.2) | 3 (14.3) |
| II | 0 | 1 (9.1) | 1 (4.8) |
| III | 2 (20.0) | 3 (27.3) | 5 (23.8) |
| IV | 6 (60.0) | 5 (45.5) | 11 (52.4) |
| Previous anticancer therapy lines | |||
| 1 | 6 (60.0) | 9 (81.8) | 15 (71.4) |
| 2 | 3 (30.0) | 2 (18.2) | 5 (23.8) |
| 3 | 1 (10.0) | 0 | 1 (4.8) |
Data are presented as n (%) unless otherwise indicated.
Abbreviations: ECOG = Eastern Cooperative Oncology Group; MALT = mucosa-associated lymphoid tissue; R-B = rituximab plus bendamustine; R-CHOP = rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; SRI = safety run-in.
a
Data for 3 patients in the R-B SRI were missing/not applicable.
b
Data for 1 patient in the R-B SRI were missing/not applicable.